Ritedose Pharmaceuticals Launches Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml)

COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation solutions produced by Ritedose Pharmaceuticals and is available in cartons of 60 vials. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 27-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.

“We’re pleased to continue expanding our generics portfolio,” said Ritedose President and CEO Jody Chastain. “With a broad array of products currently in development and launching soon, we’ll be able to offer our clients even more of the many products they regularly need with ample, reliable supplies.”

Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and packaging of single-dose medication, and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 27-year track record includes delivery of more than 10 billion doses since 2012 without interruption, and its current capacity is 2 billion units annually.

To request more information on Ritedose products or to place an order, contact us.

Pioneers in aseptic production of sterile, single-dose medication